Reply
We thank Drs Littmann and Monroe for their letter to the editor. The numbers stemming from the calculations presented by Drs Littmann and Monroe are perhaps not as dramatic as suggested, in that the incidence of 5 per 10 000 is limited to those regions of the world where the Brugada syndrome is endemicparts of Southeast Asia and Japan. The incidence of 66 per 10 000 quoted in our consensus report 1 is limited to a small region in Japan. Moreover, it is important to recognize that the actual prevalence of the syndrome is a sensitive function of the criteria applied in the individual studies, 2 which is one of the main reasons for the consensus conference and report. With less than a decade since the identification of the Brugada syndrome as a distinct clinical entity, it would be safe to conclude that data on its worldwide incidence remain out of reach. We take no issue with the other excellent points made in the letter and consider the question of how one might go about screening for those at risk for sudden death as rhetorical in that this is the subject of the consensus document.
